Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04559945 · ClinicalTrials.gov registry record · NA

The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

A NA study of Bradycardia and Cardiac Rhythm Disorder, sponsored by Abbott Medical Devices.

Active
Registry status
NA
Development phase
326
Enrollment target
20
Study locations

NCT04559945: Active NA study of Bradycardia and Cardiac Rhythm Disorder, sponsored by Abbott Medical Devices.

NCT04559945 is a NA study of Bradycardia and Cardiac Rhythm Disorder that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 326 participants, below the 4,401-participant average among 29 other Bradycardia trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04559945, a NA study of Bradycardia and Cardiac Rhythm Disorder, is active but no longer recruiting, sponsored by Abbott Medical Devices.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
326 participants
Enrollment target
20
Study locations

Study Summary

prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.

Primary Outcome

Complication is any device-or-procedure related serious adverse event, or serious adverse device effect, including those that prevented initial implantation. Complications possibly related or related to COVID-19 were excluded. Percentage of participants free from complications are reported

Interventions

  • DEVICE Aveir VR Leadless Pacemaker System

Study Locations (20)

California

  • University of Southern California - Long Beach
  • Premier Cardiology Inc - Newport Beach
  • Huntington Memorial Hospital - Pasadena

Kentucky

  • St. Elizabeth Medical Center - South Unit - Edgewood
  • Baptist Health Lexington - Lexington
  • University of Kentucky - Lexington

Alabama

  • University Hospital - University of Alabama at Birmingham (UAB) - Birmingham
  • The Heart Center PC - Huntsville

Florida

  • Naples Heart Rhythm Specialists PA - Naples
  • Orlando Health - Orlando

Georgia

  • Piedmont Athens Regional Medical Center - Athens
  • Redmond Regional Medical Center - Rome

Kansas

  • Kansas University Medical Center - Kansas City
  • Kansas City Cardiac Arrhythmia Research Foundation - Overland Park

Michigan

  • Ascension St. John Hospital - Detroit
  • Sparrow Clinical Research Institute - Lansing

Arizona

  • Honor Health - Scottsdale

Trial Details

FieldValue
Enrollment Target 326 participants
Start Date 2020-11-13
Est. Completion 2023-08-31
Phase NA
Abbott Medical Devices

261 total trials

What the registry record for NCT04559945 still lists

NCT04559945 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, below the 4,401-participant average among 29 other Bradycardia trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Bradycardia appearing as the primary indexed condition, and to 1 intervention - of which Aveir VR Leadless Pacemaker System is the first listed.

NCT04559945 names 20 study sites across 11 states, led by California, Kentucky, Alabama.

Frequently Asked Questions

What is clinical trial NCT04559945 about?

NCT04559945 is a clinical study titled "The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System". prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.

What is the current status of trial NCT04559945?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 326 participants. The study started on 2020-11-13. Estimated completion is 2023-08-31.

What conditions does trial NCT04559945 study?

This clinical trial studies the following conditions: Bradycardia, Cardiac Rhythm Disorder.

What interventions are being tested in trial NCT04559945?

The interventions under investigation include: Aveir VR Leadless Pacemaker System (DEVICE).

Who is sponsoring clinical trial NCT04559945?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04559945 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bradycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04559945's enrollment target sits among peer trials

326 20th of 29 higher than 10 of 29 other Bradycardia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bradycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06410144 · 326 participants · NA

    Chronic Kidney Disease-Education (CKD-EDU)

  • NCT06586619 · 326 participants · NA

    A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV

  • NCT07040566 · 326 participants · Phase 2

    A Trial of Varenicline for E-cigarette Cessation

  • NCT07165860 · 326 participants · NA

    Clinical Trial to Reduce Perinatal Intimate Partner Violence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04559945, the US trial registry maintained by the National Library of Medicine. NCT04559945 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.